ResMed (RMD) Q3 2012 Earnings Call April 26, 2012 4:30 pm ET Executives Peter C. Farrell - Founder, Executive Chairman, Chief Executive Officer and President Brett A. Sandercock - Chief Financial Officer and Principal Accounting Officer Unknown Executive - Michael J. Farrell - President of Americas Operations Geoff Neilson - President of Respiratory Care Strategic Business Unit Robert Douglas - Chief Operating Officer Analysts David Low - Deutsche Bank AG, Research Division Ben Andrew - William Blair & Company L.L.C., Research Division Matthew Prior - BofA Merrill Lynch, Research Division Joanne K. Wuensch - BMO Capital Markets U.S. David C. Clair - Piper Jaffray Companies, Research Division Saul Hadassin - Crédit Suisse AG, Research Division David Stanton - Nomura Securities Co. Ltd., Research Division Steven D. Wheen - JP Morgan Chase & Co, Research Division Ben C. Haynor - Feltl and Company, Inc., Research Division Michael Matson - Mizuho Securities USA Inc., Research Division PresentationOperator
Good day, ladies and gentlemen, and welcome to the Third Quarter 2012 ResMed Incorporated Earnings Conference Call. My name is Angela, and I will be your coordinator for today. [Operator Instructions] As a reminder, this conference is being recorded for replay purposes. The company has asked me to read -- address certain matters. First, ResMed does not authorize the recording of any portion of this conference call for any purpose. Second, during the conference call, ResMed may make forward-looking statements such as: Projections of future revenue or earnings, new product development or new markets for the company's products. These statements are made under the Safe Harbor provision of the Private Securities Litigation Reform Act of 1995. Risks and uncertainties exist that could cause actual results to materially differ from the forward-looking statements.